The Prostakath stent: four years' experience.
The Prostakath stent is recommended as an option in the treatment of acute urinary retention in the patient at high risk from a transurethral resection of the prostate. In 57 of 64 patients with acute retention, voiding was re-established. A stent-related problem developed in 16 patients and further treatment was usually required. Patients with satisfactorily functioning stents have been followed up for 12.0 +/- 9.9 months. The most frequent complication was displacement of the stent. Infection and stone formation were uncommon. Our results do not support the use of the Prostakath in patients with symptoms of outflow obstruction or chronic retention.
Thomas
P J
PJ
Department of Urology, Brighton General Hospital.
Britton
J P
JP
Harrison
N W
NW
D000208:Acute Disease; D002408:Catheters, Indwelling; D004866:Equipment Contamination; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000601:surgery; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome; D014546:Urinary Catheterization; D016055:Urinary Retention / Q000601:surgery*